title: Near elimination of varicella deaths in the US after implementation of the vaccination program.
abstract: OBJECTIVE
  Varicella has been preventable by vaccination in the United States since 1995. Previous studies reported a 66% decline in mortality rate during the first 6 years of the program. Since then, vaccination coverage has increased substantially. We updated the analysis of US varicella mortality for 2002-2007 and assessed the impact of the first 12 years of the US varicella vaccination program on varicella deaths.
  
  
  METHODS
  National data on deaths for which varicella was listed as an underlying or contributing cause were obtained from the Mortality Multiple Cause-of-Death records from the US National Center for Health Statistics. We calculated the age-adjusted and age-specific mortality rates for 2002-2007 and trends since the prevaccine years.
  
  
  RESULTS
  During the 12 years of the mostly 1-dose US varicella vaccination program, the annual average mortality rate for varicella listed as the underlying cause declined 88%, from 0.41 per million population in 1990-1994 to 0.05 per million population in 2005-2007. The decline occurred in all age groups, and there was an extremely high reduction among children and adolescents younger than 20 years (97%) and among subjects younger than 50 years overall (96%). In the last 6 years analyzed (2002-2007), a total of 3 deaths per age range were reported among children aged 1 to 4 and 5 to 9 years, compared with an annual average of 13 and 16 deaths, respectively, during the prevaccine years.
  
  
  CONCLUSIONS
  The impressive decline in varicella deaths can be directly attributed to successful implementation of the 1-dose vaccination program. With the current 2-dose program, there is potential that these most severe outcomes of a vaccine-preventable disease could be eliminated.
authors.affiliation: Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. mmarin@cdc.gov
authors.forename: Mona
authors.initials: M
authors.lastname: Marin
authors.forename: John X
authors.initials: JX
authors.lastname: Zhang
authors.forename: Jane F
authors.initials: JF
authors.lastname: Seward
mesh_terms: D000293:Adolescent; D000328:Adult; D002644:Chickenpox / Q000401:mortality* / Q000517:prevention & control*; D019433:Chickenpox Vaccine / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D014481:United States / Q000453:epidemiology; D014611:Vaccination / Q000639:trends*; D055815:Young Adult
chemical_list: D019433:Chickenpox Vaccine